VYNE Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NJ, 08807
Mailing Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NJ, 08807
Phone
800-775-7936
Fiscal Year End
1231
EIN
453757789
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 10-K Annual financial report | February 27, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
Annual Reports
10-K
February 27, 2026
- Proposed merger with Yarrow aims to fundamentally transform VYNE's business and strategic direction.
- Developing a BET inhibitor platform to treat immune-inflammatory conditions, with lead candidates VYN201 and VYN202.
Material Events
8-K
Financial Distress
March 11, 2026
High Impact
- Nasdaq granted VYNE Therapeutics an extension until September 7, 2024, to regain compliance with the minimum bid price requirement.
- A Nasdaq listing is crucial for VYNE's ability to raise money, maintain public profile, and fund its biopharmaceutical research and development.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.